PTCy and “The Story of the Three Bears”

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-01065-0.

    Article  PubMed  Google Scholar 

  2. 2.

    Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.

    CAS  Article  Google Scholar 

  3. 3.

    Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.

    CAS  Article  Google Scholar 

  4. 4.

    Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolanos-Meade J, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv. 2017;1:288–92. https://doi.org/10.1182/bloodadvances.2016002766.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9. https://doi.org/10.1182/blood.2019000487.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502–8. https://doi.org/10.1182/blood-2015-10-672071.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770–9. https://doi.org/10.1182/bloodadvances.2020001729.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018;2:2226–9. https://doi.org/10.1182/bloodadvances.2018019208.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018;132:9–16. https://doi.org/10.1182/blood-2018-02-811174.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020;126:2193–205. https://doi.org/10.1002/cncr.32796.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T-cell dysfunction and suppression. J Clin Invest. 2019;129:2357–73.

    Article  Google Scholar 

  12. 12.

    Montoro J, Piñana JL, Hernández-Boluda JC, Hernani R, Lorenzo I, Pérez A, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-0921-6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Lin C-J, Vader JM, Slade M, Dipersio JF, Westervelt P, Romee R. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. Cancer. 2017;123:1800–9. https://doi.org/10.1002/cncr.30534.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Yeh J, Whited LK, Saliba RM, Rondon G, Popat UR. Cardiac toxicities after HLA-matched allogeneic hematopoietic cell transplantation (Allo-HCT): post-transplant cyclophosphamide (PTCy) is not associated with higher incidence of cardiotoxicity. Biol Blood Marrow Transplant. 2020;26:S393–4. https://doi.org/10.1016/j.bbmt.2019.12.323.

    Article  Google Scholar 

  15. 15.

    Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Bolaños-Meade J, et al. Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy. Biol Blood Marrow Transplant. 2017;23:612–7. https://doi.org/10.1016/j.bbmt.2016.12.640.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, et al. Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide. Biol Blood Marrow Transpl. 2018. https://doi.org/10.1016/j.bbmt.2018.12.767.

    Article  Google Scholar 

  17. 17.

    Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, et al. Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2018;24:1022–8. https://doi.org/10.1016/j.bbmt.2018.01.011.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Dezern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, et al. Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2020. https://doi.org/10.1016/j.bbmt.2020.07.037.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vedran Radojcic.

Ethics declarations

Conflict of interest

VR—Consultant: Regeneron Pharmaceuticals. LL—Consultant/Advisory Board: AbbVie, Precision Biosciences, Talaris; Research Support: Genentech and Merck; Patent Holder: WindMiL Therapeutics.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Radojcic, V., Luznik, L. PTCy and “The Story of the Three Bears”. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01123-7

Download citation

Search